Using virtual reality to improve cognitive functions in older adults

Virtual Sail 3D - A Feasibility Study for Enhancing Cognitive Functions in Elderly People

Not applicable Interventional University of Cagliari · NCT06579378

This study is testing if a 6-week virtual reality program can help older adults with mild cognitive impairment improve their memory and attention while having fun.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment40 (estimated)
Ages65 Years and up
SexAll
SponsorUniversity of Cagliari Academic / other
Locations1 site (Cagliari, CA)
Trial IDNCT06579378 on ClinicalTrials.gov

What this trial studies

This research project evaluates the feasibility and preliminary effectiveness of a 6-week intervention using the 3D immersive virtual reality software 'CEREBRUM' to enhance cognitive functions in elderly individuals with mild cognitive impairment. The intervention involves engaging virtual sailing scenarios designed to improve memory, attention, and other cognitive skills while also promoting enjoyment. The study aims to address the risk factors associated with cognitive decline through non-pharmacological methods, leveraging the growing interest in immersive technology for rehabilitation. Participants will engage in cognitive remediation activities tailored to their needs, with assessments conducted to measure improvements in cognitive performance.

Who should consider this trial

Good fit: Ideal candidates for this study are elderly individuals aged 65 and older who are living independently and have mild cognitive impairment.

Not a fit: Patients with severe neurological conditions, significant mobility issues, or other serious health problems may not benefit from this study.

Why it matters

Potential benefit: If successful, this intervention could provide a novel, engaging method to enhance cognitive functions and delay cognitive decline in older adults.

How similar studies have performed: Previous studies have shown success in using cognitive remediation interventions, but the specific application of immersive 3D virtual reality for cognitive enhancement in this population is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 65 years or older
* Sex: all
* Living independently,
* Without conditions that would prevent them from participating in the activities of the experimental intervention "VSail 3D,"
* Without severe issues with autonomous mobility
* With Mild Cognitive Impairment (MCI) according to Addenbrooke's Cognitive Examination for cognitive functions (ACE-R), which also includes the Mini-Mental State Examination (MMSE), with the following ranges: ACE = 66.93-79.86 and/or MMSE = 21-25.
* Signing the informed consent

Exclusion Criteria:

* severe cardiovascular conditions
* severe issues with autonomous mobility
* severe metabolic disorders not pharmacologically compensated
* severe neurological conditions that prevent from participating in the experimental protocol, such as a stroke within the past 2 years, Parkinson's disease, epilepsy, or dementia (Alzheimer's, vascular, etc.)
* severe ongoing bronchopulmonary disorders
* severe ongoing renal disorders
* glaucoma, retinal detachment, or other serious vision conditions that do not allow the safe use of 3D virtual reality technology
* active malignant neoplasm that do not allow the hinders participation in the intervention.

Where this trial is running

Cagliari, CA

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Mild Cognitive ImpairmentVirtual realityFeasibilityCognitive functionsSailAdvances Technologies Laboratory
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.